Dogwood Therapeutics, Inc.
SP16 IV
neuropathy and inflammation caused by cancer chemotherapy
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for SP16 IV in neuropathy and inflammation caused by cancer chemotherapy are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Commencing dosing patients in the forthcoming SP16 Phase 1b study by mid-2026.”